PMID- 17013741
OWN - NLM
STAT- MEDLINE
DCOM- 20070130
LR  - 20181201
IS  - 0949-2658 (Print)
IS  - 0949-2658 (Linking)
VI  - 11
IP  - 5
DP  - 2006 Oct
TI  - Evaluation of biodistribution by local versus systemic administration of 
      99mTc-labeled pamidronate.
PG  - 512-20
AB  - BACKGROUND: There is an emerging interest in utilizing local and systemic 
      administration of bisphosphonates in orthopedics. The primary objective of this 
      study was to use (99m)Tc-pamidronate ((99m)Tc-PAM) as a tool and compare bone and 
      tissue uptake by local versus systemic administration. METHODS: (99m)Tc-PAM was 
      administered intravenously (i.v.), subcutaneously (s.c.) and by direct 
      application (d.a.) on a surgically exposed and fractured femur (d.a.#f). The 
      animals were imaged at 2 h and 24 h after administration and then killed. Organs 
      were harvested, and their radioactivity was estimated. Specific uptake in the 
      right femur was compared between groups, as was systemic exposure to (99m)Tc PAM. 
      RESULTS: Bone uptake of (99m)Tc-PAM in the i.v. and s.c. groups was 2.2 +/- 0.15 
      and 0.65 +/- 0.07% ID/g, respectively, at the 2 h time point. Uptake by 
      surgically exposed right femur (d.a) was 5.15 +/- 0.26% ID/g, 134% higher than 
      the femoral uptake by the i.v. method (P < 0.05). In the presence of exposed bone 
      when the femur was fractured (d.a.#f), the uptake was 7.89 +/- 0.46% ID/g, a 
      further 50% increase (P < 0.05). The uptake of (99m)Tc-PAM increased after 24 h 
      of application to 2.4 +/- 0.15, 1.53 +/- 0.09, 7.94 +/- 0.99, and 13.2 +/- 0.80% 
      ID/g) for i.v., s.c., d.a., and d.a.#f methods, respectively. The increases in 
      uptake for the d.a. methods were significantly higher than for the local methods 
      at the 24-h time point (P < 0.05). Although renal uptake was comparable with the 
      i.v. and s.c. methods (0.22 +/- 0.03 and 0.22 +/- 0.04% ID/g), it was 
      significantly lower with the d.a. methods (0.05 +/- 0.07 and 0.16 +/- 0.07% ID/g) 
      (P < 0.05). The corresponding urinary excretion was 55%, 45%, 36%, and 35% of the 
      injected dose at 24 h. CONCLUSIONS: The results indicate that the bone uptake of 
      (99m)Tc-PAM was significantly higher (P = 0.001) and the kidney uptake 
      significantly lower (P = 0.004) with the d.a. methods than with the i.v. or s.c. 
      method. The findings indicate the need for further study into the potential of 
      local administration of bisphosphonates in the presence of orthopedic 
      indications.
FAU - Kumar, Divesh
AU  - Kumar D
AD  - Department of Nuclear Medicine, University of Macquarie, Department of Biological 
      Science, The Children's Hospital at Westmead and the Westmead Hospital, Westmead, 
      Australia.
FAU - Kumar, Vijay
AU  - Kumar V
FAU - Little, David G
AU  - Little DG
FAU - Howman-Giles, Robert B
AU  - Howman-Giles RB
FAU - Wong, Effie
AU  - Wong E
FAU - Ali, Sinan O
AU  - Ali SO
LA  - eng
PT  - Journal Article
PL  - Japan
TA  - J Orthop Sci
JT  - Journal of orthopaedic science : official journal of the Japanese Orthopaedic 
      Association
JID - 9604934
RN  - 0 (Bone Density Conservation Agents)
RN  - 0 (Diphosphonates)
RN  - 7440-26-8 (Technetium)
RN  - EC 3.6.1.- (GTP Phosphohydrolases)
RN  - OYY3447OMC (Pamidronate)
SB  - IM
MH  - Administration, Topical
MH  - Animals
MH  - Bone Density Conservation Agents/administration & dosage/*pharmacokinetics
MH  - Diphosphonates/administration & dosage/*pharmacokinetics
MH  - Disease Models, Animal
MH  - Femoral Fractures/diagnostic imaging/drug therapy/metabolism
MH  - Femur/diagnostic imaging/drug effects/*metabolism
MH  - GTP Phosphohydrolases
MH  - Injections, Intravenous
MH  - Injections, Subcutaneous
MH  - Male
MH  - Pamidronate
MH  - Radionuclide Imaging
MH  - Rats
MH  - Rats, Wistar
MH  - Technetium/administration & dosage/*pharmacokinetics
EDAT- 2006/10/03 09:00
MHDA- 2007/01/31 09:00
CRDT- 2006/10/03 09:00
PHST- 2006/02/02 00:00 [received]
PHST- 2006/05/24 00:00 [accepted]
PHST- 2006/10/03 09:00 [pubmed]
PHST- 2007/01/31 09:00 [medline]
PHST- 2006/10/03 09:00 [entrez]
AID - S0949-2658(15)32510-0 [pii]
AID - 10.1007/s00776-006-1046-5 [doi]
PST - ppublish
SO  - J Orthop Sci. 2006 Oct;11(5):512-20. doi: 10.1007/s00776-006-1046-5.